The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?

Abstract

Purpose of review: Atherosclerosis (AS) is a progressive disease characterized by initial lipid deposition, endothelial dysfunction, inflammation, fibrocalcific lesions formation, and ultimately, plaque instability intensified and rupture-one of the major contributors to morbidity and mortality worldwide. The enzymes lysyl oxidase (LOX) and its LOX-like (LOXL) isoforms are copper-dependent amine oxidases that catalyze lysine-derived cross-linking in collagen and elastin, playing indispensable roles in extracellular matrix (ECM) homeostasis. This review aims to summarize current insights into the roles of LOX/LOXL in AS pathogenesis and their potential as therapeutic targets.

Recent findings: Recent studies have revealed that the LOX family exerts dual effects on the progression of AS, such as early endothelial dysfunction, vascular smooth muscle cell (VSMC) phenotypic switching, and fibrous cap stability. Dysregulated LOX expression, induced by low-density lipoprotein (LDL), low shear stress, and hormonal regulation, can worsen endothelial damage, while LOX activity may also have anti-atherogenic effects: it promotes the formation of stable fibrous cap. The LOX family contributes to both the progression and stabilization of atherosclerotic lesions through complex and stage-specific mechanisms. Understanding these multifaceted roles opens new avenues for developing LOX-targeted therapies aimed at improving plaque stability and reducing AS-related cardiovascular events.